Sermorelin was an FDA-approved drug. Today's listings are not Geref.
Historical Geref products were approved for diagnostic use and pediatric growth hormone deficiency, then discontinued and withdrawn. The main human evidence is pediatric. It does not establish modern adult anti-aging, muscle, fat-loss, sleep, or wellness claims. This guide connects every claim to the exact record and its limit.
The old Geref record answers a narrow question, not every modern Sermorelin claim.
FDA records show that Geref was approved in 1990 for diagnostic use and in 1997 for pediatric growth hormone deficiency. Both approvals were withdrawn effective June 18, 2009 after the sponsor discontinued the products. In 2013, FDA determined that the products were not withdrawn from sale for reasons of safety or effectiveness.
That history does not make a current compounded preparation or research vial Geref. Historical studies recorded growth responses in selected children. They do not establish adult anti-aging, muscle gain, fat loss, recovery, sleep improvement, energy, longevity, or a personal use protocol.
Read the Sermorelin record in four fields.
This is a sourced status snapshot, not a safety score, treatment recommendation, or seller certification. Each field links back to the detailed record below.
Historical pediatric studies
Controlled and open-label records evaluated growth responses in selected children, not modern adult wellness outcomes.
Inspect the human evidenceNarrow historical evidence
No cited trial establishes adult anti-aging, muscle, fat-loss, sleep, energy, recovery, or longevity benefit.
Audit the popular claimsGeref approvals withdrawn
Two historical approvals were withdrawn in 2009 after discontinuation and not for safety or effectiveness reasons.
Check status and destination routesDated US price boards
Molecule, historical product, human studies, and current supply are separate records.
Every useful answer must preserve the exact substance, finished product, population, outcome, manufacturer, lot, intended use, and destination country.
A 29-amino-acid GHRH fragment
FDA GSRS records sermorelin as a validated protein substance with the sequence YADAIFTNSYRKVLGQLSARKLLQDIMSR and an active-moiety relationship to sermorelin acetate. A matching name or sequence does not authenticate an online vial, pharmacy preparation, strength, purity, or sterility.
Geref was approved, then discontinued
FDA records two historical Geref approvals, one for diagnostic use and one for pediatric growth hormone deficiency. Both approvals were withdrawn effective June 18, 2009 after the sponsor discontinued the products. FDA later determined the withdrawals were not for safety or effectiveness reasons.
The main evidence is pediatric and historical
Controlled and open-label studies evaluated GHRH 1-29 in children with growth disorders. They recorded growth responses and tolerability under clinical conditions. They do not establish adult anti-aging, bodybuilding, fat-loss, sleep, recovery, or general wellness benefits.
Modern products require their own evidence
Research listings and compounded preparations are not the discontinued Geref product. FDA enforcement and recall records show why intended use, manufacturer, formulation, lot, sterility, specification, prescription route, and destination rules must be checked separately.
What the Sermorelin record shows, and what it cannot prove.
Each row puts the strongest relevant record beside the conclusion that still does not follow.
Sermorelin is an FDA-approved anti-aging peptide
FDA records show historical Geref approvals for a diagnostic use and pediatric growth hormone deficiency, followed by withdrawal of both approvals in 2009 after commercial discontinuation.
Those exact historical product approvals did not cover anti-aging, longevity, bodybuilding, fat loss, recovery, sleep, or general wellness. A past application does not transfer to a current seller vial or clinic formulation.
Sermorelin builds muscle and burns fat in adults
The cited human evidence mainly concerns growth responses in children with growth disorders and the historical diagnostic stimulation of growth hormone secretion.
A hormone response or pediatric height-velocity finding is not evidence of meaningful adult muscle gain, fat loss, body recomposition, athletic performance, or a favorable benefit-risk balance.
Sermorelin improves sleep and energy
Sermorelin acts through growth hormone-releasing-hormone biology, and hormone secretion has a physiological relationship with sleep. That mechanism is often used in promotional claims.
The cited record does not establish a dependable treatment effect for insomnia, sleep quality, fatigue, energy, cognition, or mood in a general adult population.
Sermorelin is safer than growth hormone
Historical pediatric studies generally reported tolerability, and one review identified transient facial flushing and injection-site pain as common events. FDA found Geref was not withdrawn for safety or effectiveness reasons.
That does not prove superiority or safety for a different population, indication, formulation, dose, duration, supplier, or combination. Comparative pediatric results were mixed, and the old product record does not authenticate a modern preparation.
Compounded or research Sermorelin is the same as Geref
A current product may use the sermorelin or sermorelin acetate name and may refer to the same active-moiety vocabulary recorded by FDA.
Geref approval belonged to exact NDAs, strengths, formulations, manufacturing controls, labels, and supply chains. FDA recall records document sterility and specification failures in separate compounded products.
A certificate of analysis proves a Sermorelin vial is safe
A well-matched laboratory report may support a limited result for the tested sample, such as identity, quantity, purity, or a named contaminant test.
It does not create approval, prove clinical benefit, replace sterility controls, cover untested hazards, establish lawful supply, or show that the tested sample and delivered vial are the same lot without a credible chain of custody.
The main studies measured growth in children, not wellness in adults.
Height velocity, a diagnostic hormone response, body composition, sleep quality, strength, function, and longevity are different outcomes. One cannot stand in for another.
One-year multicenter pediatric study
- Identity
- GHRH 1-29 under controlled clinical use
- Design
- Multicenter, open-label study
- Participants
- 110 children enrolled; 86 in efficacy analysis
Mean height velocity increased during the first year and the investigators reported no adverse changes in the monitored biochemical or hormonal measures. The open-label design, selected pediatric population, and historical product context do not establish adult wellness benefit or current-product safety.
Randomized comparison with growth hormone
- Identity
- GHRH 1-29 versus growth hormone
- Design
- Three-group randomized clinical trial
- Participants
- 60 children with hypothalamic growth hormone deficiency
All groups showed growth, but the growth-hormone group had significantly greater mean height velocity than either GHRH 1-29 group at six months. The result rejects a simple claim that the releasing-hormone fragment was universally equal or superior.
Dose-group growth response trial
- Identity
- GHRH 1-29 versus growth hormone
- Design
- Randomized, three-regimen clinical trial
- Participants
- 43 prepubertal children
Most participants met the study's growth-response threshold. The higher GHRH group and growth-hormone group had comparable height velocity during the short trial, while a favorable height score adjusted for bone age appeared only in the growth-hormone group.
Growth during and after GHRH 1-29
- Identity
- GHRH 1-29 in short, slowly growing children
- Design
- Two-group prospective treatment study
- Participants
- 24 children
Growth rates increased during treatment. Six months after discontinuation, overall growth rates were not significantly different from pretreatment rates, although a subset remained above baseline. This does not support a dependable lasting-effect claim after stopping.
Historical diagnostic and treatment review
- Identity
- Sermorelin and GHRH 1-29 literature
- Design
- Narrative drug review
- Participants
- Multiple historical pediatric and diagnostic records
The review described limited pediatric growth evidence, unresolved final-adult-height benefit, no direct comparison of the recommended regimen with somatropin, and transient flushing and injection-site pain as common adverse events. It is a synthesis, not a modern adult trial.
Approved, discontinued, withdrawn, then reviewed.
Approval history, current approval, discontinuation, and the reason for withdrawal are four distinct facts.
Diagnostic Geref approved
FDA records NDA 19-863 for a Geref sermorelin acetate product used to evaluate the pituitary gland's ability to secrete growth hormone.
Open the FDA application package →Pediatric Geref approved
FDA records NDA 20-443 for treatment of idiopathic growth hormone deficiency in children with growth failure.
Open the FDA orphan record →Approvals withdrawn, reason clarified
Withdrawal became effective in 2009. FDA's 2013 review found the discontinued products were not withdrawn for reasons of safety or effectiveness.
Read the full FDA notice →Sermorelin, Ipamorelin, and Tesamorelin are not interchangeable.
Shared growth-signaling language does not make three different molecules equivalent or transfer one product's evidence and approval to another.
Sermorelin
A 29-amino-acid growth hormone-releasing-hormone fragment with discontinued Geref product history and mainly pediatric human evidence.
Open the Sermorelin market board →Ipamorelin
A distinct growth hormone secretagogue with its own human pharmacology, registry, FDA safety, and research-market records. No cited head-to-head outcome trial names a winner.
Open the Ipamorelin evidence guide →Tesamorelin
The active ingredient in EGRIFTA WR, a current FDA-labelled product for a defined indication and population. That product approval does not transfer to Sermorelin.
Compare the separate market records →A current listing is not the discontinued Geref product.
These are dated US seller-page observations, not medical validation. Price and stock do not establish identity, purity, sterility, approval, seller authority, legal access, or individual suitability.
03
Three public US 5 mg pages met the current board rules. Every row preserves its source date, availability language, document route, and evidence limits.
Inspect every source row →02
Only explicit current stock language enters the available count. Ambiguous rows remain visible but cannot set the available market low.
Check source freshness →$43.00-49.49
The range excludes shipping, taxes, coupons, checkout-only discounts, and rows without a usable stock signal. It is market data, not a recommendation.
Compare landed cost →Sermorelin status depends on the exact destination and product.
US FDA history is useful, but it does not decide Canadian, Australian, South African, French, Italian, Mexican, or other local rules. Check the exact product, prescription route, pharmacy, seller, import path, intended claim, and regulator record for the destination.
Twelve Sermorelin questions, answered from the exact record.
This is educational reporting, not medical advice, a prescription, emergency guidance, or a use protocol.
What is Sermorelin?
Sermorelin is a synthetic, amidated 29-amino-acid fragment of human growth hormone-releasing hormone, also searched as GHRH 1-29 or GRF 1-29. FDA GSRS records sermorelin and sermorelin acetate as related substance identities. That identity record describes the molecule, not the contents, quality, approval, or lawful status of a seller-labelled vial.
What are the proven benefits of Sermorelin?
Historical studies found diagnostic growth-hormone responses and increased height velocity in some children with growth disorders under controlled clinical care. That is the strongest cited human record. It does not establish anti-aging, adult muscle gain, fat loss, sleep improvement, injury recovery, energy, cognition, longevity, or broad wellness benefit.
Is Sermorelin FDA approved?
There is important history, but no current Geref approval should be inferred from the old record. FDA approved Geref diagnostic and pediatric treatment products in 1990 and 1997, then withdrew both approvals effective June 18, 2009 after the sponsor discontinued them. FDA later determined that the products were not withdrawn from sale for safety or effectiveness reasons.
Why was Geref discontinued?
The cited Federal Register record says the sponsor notified FDA in 2008 that the Geref products were being discontinued and requested withdrawal of the NDAs. FDA later reviewed its files, literature, and postmarketing information and determined that the products had not been withdrawn for reasons of safety or effectiveness. Commercial discontinuation is not the same as a safety withdrawal.
What are the side effects of Sermorelin?
The historical review identified transient facial flushing and injection-site pain as the most commonly reported adverse events. Individual pediatric studies used clinical and laboratory monitoring and generally described tolerability. Those records do not supply a complete modern safety profile for adults, long exposure, combinations, compounded formulations, or research products with uncertain contents.
Does Sermorelin help with muscle growth, fat loss, or anti-aging?
The cited primary record does not establish those outcomes. Sermorelin can stimulate growth-hormone release under specific conditions, but a hormone response is a biomarker, not proof of meaningful adult body-composition change, strength, function, recovery, longevity, or net clinical benefit. Historical pediatric growth studies cannot be repurposed as adult anti-aging trials.
Does Sermorelin improve sleep?
The cited evidence does not establish Sermorelin as an insomnia or sleep-quality treatment. Promotional explanations often connect normal growth-hormone rhythms with sleep, but biological plausibility is not a clinical outcome. A dependable answer would require controlled adult sleep studies with a defined product, population, comparison, duration, outcomes, and adverse-event record.
Sermorelin vs Ipamorelin: are they the same?
No. Sermorelin is a 29-amino-acid growth hormone-releasing-hormone fragment. Ipamorelin is a distinct ghrelin-receptor agonist and growth-hormone secretagogue. Their molecular identities, receptors, historical records, studies, regulatory findings, and seller products are different. No cited head-to-head outcome trial proves one is safer or better for modern wellness claims.
Sermorelin vs Tesamorelin: what is the difference?
They are distinct growth-hormone-releasing-factor analogues with different sequences, product histories, evidence, and status. Tesamorelin is the active ingredient in the current FDA-labelled EGRIFTA WR product for a defined indication and population. Historical Geref approval and current EGRIFTA WR approval do not transfer between molecules or to research vials.
Is compounded Sermorelin the same as Geref?
No equivalence should be assumed. A compounded preparation may use the same active-moiety name, but Geref approval belonged to exact applications, strengths, formulation, manufacturer, label, and quality system. FDA has posted recalls involving separate compounded Sermorelin products for lack of sterility assurance or out-of-specification results, showing why each finished product and lot needs its own evidence.
What is a safe Sermorelin dosage?
This guide does not provide a personal dose, schedule, injection, mixing, cycling, or combination protocol. Historical study regimens and discontinued labels belong to specific products, populations, indications, and monitoring conditions. They should not be converted into instructions for current compounded preparations or seller-labelled research vials with different identity and quality records.
Can I buy Sermorelin legally in my country?
The answer depends on the exact product category, intended claim, prescription and pharmacy route, supplier, import path, and destination. A US research listing, clinic offer, past Geref approval, or shipment claim does not establish lawful access. Use the country and state routes linked here to check current regulator, medicine-register, pharmacy, and seller records.
Do not convert an old pediatric study into a modern self-use protocol.
The historical studies used defined clinical products, selected children, controlled conditions, and professional monitoring. A modern clinic preparation, pharmacy product, research vial, blend, and seller instruction can differ in identity, formulation, strength, impurities, sterility, storage, exposure, and intended use.
Past approval, current compounding eligibility, country access, product testing, seller availability, and individual medical care are separate records. This page does not provide dosing, reconstitution, injection, cycling, stacking, or titration instructions.